A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Doxorubicin; Paclitaxel
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-775
- Sponsors Eisai Inc
- 01 Aug 2018 Planned End Date changed from 23 Jan 2022 to 25 Jan 2023.
- 01 Aug 2018 Planned primary completion date changed from 9 Nov 2021 to 24 Feb 2022.
- 01 Aug 2018 Status changed from not yet recruiting to recruiting.